Ajanta Pharma Limited (BOM:532331)
2,910.20
-114.30 (-3.78%)
At close: May 29, 2026
Ajanta Pharma Revenue
In the fiscal year ending March 31, 2026, Ajanta Pharma had annual revenue of 54.53B INR with 17.31% growth. Ajanta Pharma had revenue of 14.22B in the quarter ending March 31, 2026, with 21.47% growth.
Revenue
54.53B
Revenue Growth
+17.31%
P/S Ratio
6.71
Revenue / Employee
5.66M
Employees
9,628
Market Cap
366.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 54.53B | 8.05B | 17.31% |
| Mar 31, 2025 | 46.48B | 4.39B | 10.44% |
| Mar 31, 2024 | 42.09B | 4.66B | 12.45% |
| Mar 31, 2023 | 37.43B | 4.02B | 12.02% |
| Mar 31, 2022 | 33.41B | 4.51B | 15.62% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dr. Reddy's Laboratories | 335.93B |
| Lupin | 279.58B |
| Jubilant Pharmova | 82.80B |
| Abbott India | 69.29B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| GlaxoSmithKline Pharmaceuticals | 38.22B |
| Viyash Scientific | 34.20B |
Ajanta Pharma News
- 26 days ago - Pharma sector stocks rises today, May 6: Wockhardt jumps 7.16%, Ajanta Pharma surges 3.56%, Lupin up 1.60% - Business Upturn
- 27 days ago - Ajanta Pharma Transcript: Q4 25/26 - Transcripts
- 27 days ago - Ajanta Pharma Slides: Q4 2026 - Filings
- 27 days ago - Ajanta Pharma Quarterly report: Q4 2026 - Filings
- 27 days ago - Ajanta Pharma announces re-appointment of auditors for FY 2026-27 - Business Upturn
- 27 days ago - Ajanta Pharma grants 1,45,000 stock options and cancels 850 under ESOP plan - Business Upturn
- 27 days ago - Ajanta Pharma Q4 Results: Revenue jumps 21.5% YoY to Rs 1,421.64 crore, net profit up 18.4% - Business Upturn
- 5 weeks ago - Ajanta Pharma receives five observations from US FDA after facility inspection - Business Upturn